Seeking Alpha: In-Line Doesn't Cut It For NuVasive

Small-cap spine specialist NuVasive (NUVA) may have reported basically in-line numbers for the second quarter, but that's not helping its shareholders today. Although the company continues to grow share in the stagnant U.S. spine market, investors are jittery about management's ability to hit the bold target of 20%-plus operating margins down the road. Add in a subpoena from the OIG, persistent worries that the spine market opportunity isn't what it used to be, and a fairly robust valuation, and it's not as hard to understand the big drop in the shares.

Please read the full article at Seeking Alpha:
In-Line Doesn't Cut It For NuVasive